• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Mankind Pharma Ltd.
    30 Jul 2025
    2579.60
    -0.75%
    Mankind Pharma Q1 Results Preview: Revenue Likely To Rise, Net Profit May Decline
    Mankind Pharma Q1 Results Preview: Revenue Likely To Rise, Net Profit May Decline
    NDTV Profit
    As per Bloomberg estimates, Mankind Pharma's consolidated revenue for the first quarter is expected to rise year-on-year to Rs 3,605.53 crore.
    Copy LinkShare onShare on Share on Share on
    Mankind Pharma Ltd. has an average target of 2840.50 from 2 brokers.
    logo
    Wockhardt Ltd.
    29 Jul 2025
    1518.00
    -0.61%
    How Wockhardt's bet on multi-drug resistant infections is paying off
    Business Standard
    In India, Zaynich will be positioned as a third-line treatment, primarily for ICU patients when other antibiotics have failed
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 171 to 186 in Jun 2025 qtr.
    logo
    AstraZeneca Pharma India Ltd.
    29 Jul 2025
    Show Cause Notice
    9003.50
    -0.75%
    AstraZeneca Weighs Direct-To-Patient Drug Sales In US
    AstraZeneca Weighs Direct-To-Patient Drug Sales In US
    NDTV Profit
    Earlier this month, fellow European drugmaker Roche Holding AG said it was looking into direct sales to bypass players like pharmacy benefit managers.
    Copy LinkShare onShare on Share on Share on
    AstraZeneca Pharma India Ltd. has gained 32.41% in the last 1 Year
    logo
    Piramal Pharma Ltd.
    29 Jul 2025
    200.67
    0.25%
    Funding in bio-pharma sector still uncertain and inconsistent: Piramal Pharma Chairperson
    Business Line
    Says Piramal has earmarked about $120 million this year for capacity expansion
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 257 to 247 in Jun 2025 qtr
    Piramal Pharma Q1 Results: Net Loss At Rs 82 Crore, Revenue Falls
    NDTV Profit | 29 Jul 2025 1 more
    Piramal Pharma Q1 net loss at 82 crore
    Business Line | 29 Jul 2025
    logo
    Piramal Pharma Ltd.
    29 Jul 2025
    200.67
    0.25%
    Piramal Pharma sees US CDMO softness, eyes $2 billion topline by FY30
    Business Standard
    US biotech funding slowdown hits Piramal's CDMO business as company expands sterile injectables facility and maintains long-term growth targets
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 257 to 247 in Jun 2025 qtr
    logo
    Strides Pharma Science Ltd.
    29 Jul 2025
    909.75
    -0.14%
    Strides Pharma Profit Rises 81% To Rs 114 Crore In June Quarter
    Strides Pharma Profit Rises 81% To Rs 114 Crore In June Quarter
    NDTV Profit
    Revenue rose to Rs 1,120 crore for the June quarter against Rs 1,054 crore in the year-ago period, Strides Pharma Science said in a regulatory filing.
    Copy LinkShare onShare on Share on Share on
    Strides Pharma Scien.. has an average target of 1874.00 from 1 broker.
    logo
    Jubilant Pharmova Ltd.
    29 Jul 2025
    1122.30
    -0.20%
    Jubilant Pharmova Q1 Results: Net Profit Up 49% To Rs 103 Crore
    Jubilant Pharmova Q1 Results: Net Profit Up 49% To Rs 103 Crore
    NDTV Profit
    Revenue from operations rose to Rs 1,901 crore in the April-June quarter as compared with Rs 1,732 crore in the year-ago period, Jubilant Pharmova said in a regulatory filing.
    Copy LinkShare onShare on Share on Share on
    Jubilant Pharmova Ltd. is trading below its 50 day SMA of 1129.5
    logo
    Torrent Pharmaceuticals Ltd.
    29 Jul 2025
    3566.20
    -0.49%
    Torrent Pharma shares hit 52-week high post Q1 results
    Business Line
    Brokerages bullish on Torrent Pharma following its results. Most firms lift target prices
    Copy LinkShare onShare on Share on Share on
    Torrent Pharmaceuticals Ltd. is trading below its 30 day SMA of 3615.4
    Torrent Pharma gains over 2% after Q1 results; what should you do?
    Business Standard | 29 Jul 2025 4 more
    Torrent Pharma Share Price Gains After Citi Hikes Price Target Post Q1 Results
    NDTV Profit | 29 Jul 2025
    Torrent Pharma Q1 Review: Citi Hikes Target Price Here's Why
    NDTV Profit | 29 Jul 2025
    Torrent Pharma Q1 profit rises 20% to 548 cr on strong global sales
    Business Standard | 28 Jul 2025
    Torrent Pharma's net profits grow 20% to 548 cr during Q1, FY26
    Business Line | 28 Jul 2025
    logo
    Ajanta Pharma Ltd.
    29 Jul 2025
    2579.10
    0.28%
    Ajanta Pharma Poised To Deliver Double Digit Growth, Says Systematix Maintaining 'Buy' Post Strong Q1 Results
    Ajanta Pharma Poised To Deliver Double Digit Growth, Says Systematix Maintaining 'Buy' Post Strong Q1 Results
    NDTV Profit
    Systematix retains its forecasts on Ajanta and maintain Buy with a target price of Rs 3,293 based on 35x FY27E earnings per share.
    Copy LinkShare onShare on Share on Share on
    Ajanta Pharma Ltd. has an average target of 3022.00 from 5 brokers.
    Ajanta Pharma Q1 Net Profit Rises 4% To Rs 255 Crore
    NDTV Profit | 28 Jul 2025 1 more
    Ajanta Pharma net profit rises 4% to 255 cr in June qtr
    Business Line | 28 Jul 2025
    logo
    Laurus Labs Ltd.
    29 Jul 2025
    896.05
    0.05%
    Laurus Labs Targets 55-60% Gross Margin In FY26 On CDMO Expansion
    Laurus Labs Targets 55-60% Gross Margin In FY26 On CDMO Expansion
    NDTV Profit
    The CDMO segment will account for 50% of the company's revenue in the medium to long term.
    Copy LinkShare onShare on Share on Share on
    Laurus Labs Ltd. has an average target of 686.25 from 4 brokers.
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd